Research study · The Journal of Clinical Psychiatry · 2024
A Systematic Review of the Clinical Effects of Cannabis and Cannabinoids in Posttraumatic Stress Disorder Symptoms and Symptom Clusters
Verified on PubMed Systematic review or meta-analysis
A 2024 systematic review in The Journal of Clinical Psychiatry tested cannabis in post-traumatic stress disorders. Out of 10 non-CUD studies examining overall PTSD symptoms, 5 suggested benefits and 5 suggested no effect or worsening. This review suggests that while specific symptom clusters like nightmares may improve for some patients without a substance use disorder.
In plain language
Study overview
While cannabinoids may offer targeted relief for specific PTSD symptoms like nightmares and sleep disturbances (Cluster B and E), current evidence does not support major global improvements in overall PTSD severity. Furthermore, frequent use or concurrent Cannabis Use Disorder (CUD) is strongly linked to worsening symptom trajectories, increased suicidality, and aggressive behaviors, necessitating careful screening and caution in clinical practice.
Findings
Out of 10 non-CUD studies examining overall PTSD symptoms, 5 suggested benefits and 5 suggested no effect or worsening. All 3 studies evaluating patients with comorbid PTSD and CUD reported risks for worsening of overall symptoms and slower rate of improvement. Cannabinoids showed targeted benefits for Cluster B (nightmares/distressing dreams via nabilone and THC/CBD) and Cluster E (sleep improvements/hyperarousal). Cannabis use was associated with increased risks of suicidal ideation, suicidal behavior, and violent behavior in certain cohorts.
The deeper readScientific analysis
Objective: Given the high rate of comorbid posttraumatic stress disorder (PTSD) and cannabis use, it is critical that further research be conducted to address the associated benefits and risks of cannabis use in this population. This systematic review evaluated evidence on the effects of cannabis and cannabinoids on PTSD symptoms and PTSD clusters. Data Sources: A systematic search of PubMed, PsycINFO, and EMBASE databases was performed using terms related to cannabis, cannabinoids, and PTSD. Peer-reviewed studies available online in English and published from January 1990 through February 2023 were considered. Study Selection: Included studies were experimental or observational in design, were conducted in cannabis-using patients with PTSD, used validated measures of PTSD, and were published in English. Data Extraction: Extracted information included study aims, study design, sample size and sex, comparator group, cannabis-related characteristics, psychometric instruments, and relevant clinical findings regarding overall PTSD symptoms and cluster symptoms. Results: Fourteen studies were included, 3 in a comorbid PTSD and cannabis use disorder (CUD) sample and 11 in a non-CUD sample. Of the 10 studies examining overall PTSD symptoms in a non-CUD sample, 5 suggested benefits associated with cannabis use and 5 suggested no effect or worsening of symptoms. Four studies reported benefits of cannabis for cluster B- and E-related symptoms in a non-CUD sample. All 3 studies in cannabis-using patients with a comorbid PTSD and CUD diagnosis reported risks for worsening of overall symptoms. Conclusions: This review did not find major benefits of cannabinoids in improving overall PTSD symptoms. Some benefits with regard to cluster B and E symptoms were observed. Some risks with regard to worsening suicidal ideation and violent behavior were also reported. Individuals with a comorbid CUD diagnosis may be at greater risk for negative cannabis-related PTSD outcomes. More experimental studies are needed to determine the causal effects of cannabis and cannabinoids in PTSD.
The paper
Citation
Rodas JD, George TP, Hassan AN A Systematic Review of the Clinical Effects of Cannabis and Cannabinoids in Posttraumatic Stress Disorder Symptoms and Symptom Clusters. The Journal of Clinical Psychiatry (2024). PubMed 38353645 · DOI
Limitations the authors noted
Many studies failed to control for confounders such as tobacco, alcohol, and other substance use. Great heterogeneity in study design, outcome measures, potency, dosage, and route of administration across included studies. High average risk of bias among included studies. Many studies conducted exclusively in male military personnel and veterans, limiting generalizability.
In practice
Why this matters
This review suggests that while specific symptom clusters like nightmares may improve for some patients without a substance use disorder, clinicians should exercise caution due to evidence linking cannabis use in those with comorbid addiction to worsening overall outcomes and increased risks of suicidality.
Browse related research
Condition: Marijuana abuse Condition: Post-traumatic stress disorders Topic: Cannabinoids Topic: Cannabis Topic: Medical cannabis
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on September 20, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.